Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia by Andrea Pession, Riccardo Masetti, Carmelo Rizzari, Maria Caterina Putti, Fiorina Casale, Franca Fagioli, Matteo Luciani, Luca Lo Nigro, Giuseppe Menna, Concetta Micalizzi, Nicola Santoro, Anna Maria Testi, Marco Zecca, Andrea Biondi, Martina Pigazzi, Sergio Rutella, Roberto Rondelli, Giuseppe Basso, and Franco Locatelli Blood Volume 122(2):170-178 July 11, 2013 ©2013 by American Society of Hematology Schematic representation of the induction and consolidation courses employed for treating patients enrolled in the AIEOP AML 2002/01 trial. Andrea Pession et al. Blood 2013;122:170-178 ©2013 by American Society of Hematology Flowchart of patients enrolled in the 2000/01 AML protocol. Andrea Pession et al. Blood 2013;122:170-178 ©2013 by American Society of Hematology Eight-year probability of OS and EFS for the whole cohort of 482 children enrolled in the AIEOP AML 2002/01 trial. Andrea Pession et al. Blood 2013;122:170-178 ©2013 by American Society of Hematology Eight-year probability of OS, EFS, DFS, and CI of relapse for SR and HR children enrolled in the AIEOP AML 2002/01 trial. Andrea Pession et al. Blood 2013;122:170-178 ©2013 by American Society of Hematology